Výsledky vyhledávání - "Sridevi Palaparthy"

Efficacy of Plerixafor Administered At 5:00PM for Stem Cell Mobilization in Lymphoma and Myeloma Patients Undergoing Autologous Stem Cell Transplant

Autor: John Maciejewski, Stephanie A. Gregory, Sridevi Palaparthy, Jennifer Tornatta, Sunita Nathan, Henry C. Fung, Kent W. Christopherson, Bruce C. McLeod, Elizabeth Rich

Publikováno v: Blood. 118:4061-4061

Abstract 4061 Background: High-dose chemotherapy and/or radiotherapy are effective treatment strategies for patients with life-threatening hematologic malignancies. A critical step to the success of transplantation is achieving adequate mobilization

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::88667c99df5867c089ef095f5af1b201
https://doi.org/10.1182/blood.v118.21.4061.4061

Zobrazit plný text záznamu

CD26 Inhibition Preferentially Enhances In Vitro Migration of G-CSF + Plerixafor (AMD3100) Mobilized PB as Compared to G-CSF Mobilized PB In Multiple Myeloma Autografts

Autor: Karen Samuels, Sarah Walters, Elizabeth Mieras, Kent W. Christopherson, Elizabeth Rich, Sucheta Jagan, Henry C. Fung, Laura A. Paganessi, Chu-Myong Seong, Eun-Sun Yoo, Sridevi Palaparthy, Mary A. Enriquez

Publikováno v: Blood. 116:3714-3714

Abstract 3714 Hematopoietic stem and progenitor cell (HSC/HPC) trafficking into the bone marrow during hematopoietic stem cell transplantation (HSCT) is thought to be an important biological step that can be targeted to improve transplant efficiency

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c770912f66fd654a5d25a9a17e40a23b
https://doi.org/10.1182/blood.v116.21.3714.3714

Zobrazit plný text záznamu

Efficacy of Administration of Plerixafor (Mozobil®) at 5:00 PM for Stem Cell Mobilization (SCM) in Patients Receiving Autologous Stem Cell Transplant

Autor: Jennifer Tornatta, Henry C. Fung, Sunita Nathan, Bruce C. McLeod, Sridevi Palaparthy, John Maciejewski, Darilyn R. Rhoades

Publikováno v: Blood. 114:3218-3218

Abstract 3218 Poster Board III-155 Introduction In the phase 3 clinical trials of plerixafor plus G-CSF for SCM, plerixafor was administered at 10:00 pm on days prior to apheresis. This dosing schedule is based on the peak level of CD34+ cells in the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e0e32600ed7988593ce6fcc74e66e621
https://doi.org/10.1182/blood.v114.22.3218.3218

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání